{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:18:14Z","timestamp":1763468294474},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T00:00:00Z","timestamp":1458259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0150569","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T23:03:47Z","timestamp":1458342227000},"page":"e0150569","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a\/Ribavirin"],"prefix":"10.1371","volume":"11","author":[{"given":"Tarik","family":"Asselah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Romero-Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diethelm","family":"Messinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Bakalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,3,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"K Mohd Hanafia","year":"2013","journal-title":"Hepatology"},{"key":"ref2","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Available at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/hiv\/pub\/hepatitis\/hepatitis-c-guidelines\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/hiv\/pub\/hepatitis\/hepatitis-c-guidelines\/en\/<\/ext-link> Accessed 15 May 2015."},{"issue":"1 Suppl","key":"ref3","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"E Gower","year":"2014","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"HCV genotype 3\u2014the new treatment challenge","volume":"39","author":"J Ampuero","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"PY Bochud","year":"2009","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis","volume":"18","author":"G Nkontchou","year":"2011","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"ref7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"R Schinazi","year":"2014","journal-title":"Liver Int"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"Recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/S0168-8278(15)30151-3","article-title":"Sofosbuvir + peginterferon\/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study (abstract L05)","volume":"62","author":"GR Foster","year":"2015","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMe1513245","article-title":"Simple, effective, but out of reach? Public health implications of HCV drugs","volume":"373","author":"W Ward J","year":"2015","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJMp1400160","article-title":"Treating hepatitis C in lower-income countries","volume":"370","author":"CR Jayasekera","year":"2014","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3","volume":"357","author":"ML Shiffman","year":"2007","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/hep.23531","article-title":"Identifying hepatitis C virus genotype 2\/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin","volume":"51","author":"M Diago","year":"2010","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/hep.25892","article-title":"High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials","volume":"56","author":"P Marcellin","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl","key":"ref18","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1016\/S0168-8278(12)61122-2","article-title":"Baseline predictors for safety-related dose reductions or treatment discontinuations among peginterferon alfa-2a (40KD)\/ribavirin-treated patients and their impact on early treatment responses: GUARD-C interim analysis (abstract)","volume":"56","author":"GR Foster","year":"2012","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/sim.1742","article-title":"Presentation of multivariate data for clinical use: The Framingham Study risk score functions","volume":"23","author":"LM Sullivan","year":"2004","journal-title":"Stat Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"SJ Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/liv.12439","article-title":"A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)\/ribavirin","volume":"34","author":"P Ferenci","year":"2014","journal-title":"Liver Int"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e108751","DOI":"10.1371\/journal.pone.0108751","article-title":"Treatment of na\u00efve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA","volume":"9","author":"B Heidrich","year":"2014","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/hep.20467","article-title":"Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study","volume":"40","author":"O Dalgard","year":"2004","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3","volume":"352","author":"A Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2005.05.008","article-title":"Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C","volume":"129","author":"M von Wagner","year":"2005","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.2006.102558","article-title":"A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C","volume":"56","author":"ML Yu","year":"2007","journal-title":"Gut"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.21975","article-title":"Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response","volume":"47","author":"O Dalgard","year":"2008","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/hep.22253","article-title":"Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2\/3 infection","volume":"47","author":"M Lagging","year":"2008","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/135965350901400213","article-title":"Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response","volume":"14","author":"S Zeuzem","year":"2009","journal-title":"Antivir Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"D Ge","year":"2009","journal-title":"Nature"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.24154","article-title":"IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection","volume":"53","author":"A Moghaddam","year":"2011","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cgh.2010.07.019","article-title":"Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C","volume":"9","author":"AF St\u00e4ttermayer","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e99126","DOI":"10.1371\/journal.pone.0099126","article-title":"Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients","volume":"9","author":"R Firdaus","year":"2014","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0150569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T16:45:06Z","timestamp":1655311506000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0150569"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,18]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0150569","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,18]]}}}